Acute Lymphoblastic Leukemia Clinical Trials in Hackensack, New Jersey

3 studies are recruiting for acute lymphoblastic leukemia in Hackensack, New Jersey right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

    Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, …

    Stage
    Phase 1
    Ages
    0 and older
    Site
    Hackensack University Medical Center, Hackensack, New Jersey
    Locations
    57 in total
    Run by
    Syndax Pharmaceuticals

    See if you can join NCT04065399 on ClinicalTrials.gov

  2. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide informat…

    Stage
    Phase 1
    Ages
    Up to 22
    Site
    Hackensack University Medical Center, Hackensack, New Jersey
    Locations
    184 in total
    Run by
    PedAL BCU, LLC

    See if you can join NCT04726241 on ClinicalTrials.gov

  3. A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

    This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.

    Stage
    Phase 1
    Ages
    12 to 78
    Site
    John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
    Locations
    12 in total
    Run by
    Orca Biosystems, Inc.

    See if you can join NCT03802695 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.